Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alnylam Pharmaceuticals reports robust 2022 performance and growth opportunities

Alnylam Pharmaceuticals had a strong financial performance in 2022, driven by the success of AMVUTTRA and advancements in ATTR amyloidosis treatments.
While facing challenges such as FDA requests and the need for self-sustainability, the company is poised for growth with projected revenues and pipeline opportunities.
Opportunities lie in market expansion, innovative pipeline programs, and upcoming regulatory milestones, positioning Alnylam for continued success in RNAi therapeutics.

Alnylam Pharmaceuticals posts robust Q1 growth despite FDA challenges

Alnylam Pharmaceuticals reported strong financial performance in Q1 2023, driven by the TTR franchise and key product sales growth. Despite challenges with the FDA's partial clinical hold, the company remains optimistic about pipeline development and addressing unmet patient needs with RNAi therapeutics.

Alnylam Pharmaceuticals excels in Q2, poised for growth and innovation

Alnylam Pharmaceuticals delivered strong financial results, positive clinical data, and strategic partnerships in Q2 2023, positioning itself for continued growth.
While facing challenges such as market competition and regulatory complexities, Alnylam remains focused on innovation, patient care, and commercial success.
The company's emphasis on R&D, market positioning, and leveraging its RNAi platform underscores its commitment to advancing therapies and driving value for stakeholders.

Alnylam Pharmaceuticals reports robust Q3 growth and eyes HELIOS-B opportunities

Alnylam Pharmaceuticals delivered strong financial results in Q3 2023, showcasing growth and innovation in its product portfolio and pipeline. Despite challenges, the company remains focused on long-term strategies and seizing opportunities in the evolving healthcare landscape.

Alnylam Pharmaceuticals excels in 2023, poised for market leadership

Alnylam Pharmaceuticals demonstrated strong financial performance in 2023, with notable achievements in commercial RNAi therapeutics and franchise growth. The company's strategic focus on innovation, study optimization, and market positioning bodes well for future success and market leadership in RNAi therapeutics.

Alnylam Pharmaceuticals reports robust Q1 performance and strategic readiness

Alnylam Pharmaceuticals showcased strong financial performance, strategic focus on patient needs, and readiness for upcoming milestones.
While facing challenges in meeting guidance and ensuring successful launches, the company is well-positioned for growth and innovation.
Opportunities lie in upcoming milestones, secondary endpoint focus, and future catalysts, driving potential value creation and differentiation.

Alnylam Pharmaceuticals excels in Q2 2024, poised for sustained growth

Alnylam Pharmaceuticals demonstrated strong financial performance and clinical advancements in Q2 2024, driven by key revenue growth drivers and pipeline progress.
While facing challenges such as rising expenses, the company's strategic strengths in franchise performance and margin improvement position it well for future opportunities.
With upcoming milestones and increased guidance, Alnylam is poised to capitalize on growth prospects and maintain its position as a leader in rare disease therapeutics.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Intellia Therapeutics

Alnylam is rapidly becoming the leader in ATTR through its successful therapy, patisiran. Intellia has presented data showing even deeper reductions in TTR.

Can Intellia One-Up Alnylam In Transthyretin Amyloidosis?

Alnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a significant rise of 51% in a month.

Is Alnylam Stock Poised For More Gains After A Stellar 50% Rise In A Month?

Axsome Therapeutics

Karuna Therapeutics Inc

These three biotech companies could be headed for a buyout soon.

3 Biopharmas on Buyout Watch

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present data from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, during a late-breaker session at the 18th International Symposium on Amyloidosis (ISA) on September 8, 2022. The Company announced positive topline

Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis

It's pursuing a smart and tightly focused drug development strategy that could pay off big.

Is This Unknown Growth Stock a Buy After Its Blast Off?

Alnylam stock cooled Friday as one expert argued the company will have to run a second study of its cardiomyopathy drug to gain traction. The post Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug appeared first on Investor's Business Daily.

Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug

A gene-editing treatment from Intellia led to elevated liver enzymes in one patient with polyneuropathy, prodding NTLA stock to topple. The post Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned appeared first on Investor's Business Daily.

Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned

Beam Therapeutics

CRISPR Therapeutics

Gene editing stocks are the talk of Wall Street today as a number of biotech titans enjoy strong gains. It seems a breakthrough clinical trial from Alnylam Pharmaceuticals (NASDAQ: ALNY ) has lifted the entire industry.

Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?

Today, Alnylam Pharmaceuticals (NASDAQ: ALNY ) revealed positive top-line results for the company's transthyretin-mediated amyloidosis treatment, patisiran. Alnylam's drug reportedly met its primary endpoint for selected trial participants, and consequently, ALNY stock is roaring higher today.

Why Is Alnylam (ALNY) Stock Up 50% Today?

The RNAi drugmaker hits the mark in a rare form of heart failure.

Why Alnylam Pharmaceuticals Stock Is Vaulting Higher Today

Alnylam stock is on track to open at a record high Wednesday after its cardiomyopathy drug met every goal in a final-phase study. The post Alnylam Pharmaceuticals Is On Track To Hit A Record High — Here's Why appeared first on Investor's Business Daily.

Alnylam Pharmaceuticals Is On Track To Hit A Record High — Here's Why

Shares of Alnylam Pharmaceuticals Inc. ALNY, +1.44% soared 57.0% in premarket trading on Wednesday after the company said its investigational RNAi therapeutic for a type of heart failure met the primary endpoint in a Phase 3 clinical trial. The randomized, double-blind, placebo-controlled study enrolled 360 adult patients in 21 countries.

Alnylam's stock jumps 57% after sharing positive news for its experimental RNAi therapy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, met the primary endpoint of change from baseline in the 6-Minute Walk Test (6-MWT) at 12 months compared to placebo (p-value 0.0162). The study also met the first secondary endpoint

Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has ranked #1 on Fast Company's fourth annual list of Best Workplaces for Innovators. The 2022 Best Workplaces for Innovators ranks 100 winners from a variety of industries, including computer science, biotech, consumer packaged goods, nonprofit, education, financial services, cybersecurity, engineering, diversity, sustainability, B2B, and cons

Alnylam Ranks #1 on Fast Company's Fourth Annual List of the 100 Best Workplaces for Innovators

After decades of developing rare-disease drugs, this RNA pioneer will aim for much larger audiences.

Alnylam's Strategy Is Getting Bigger. Time to Buy?

Alnylam's (ALNY) earnings and sales fall shy of estimates in the second quarter of 2022. The company maintains its revenue guidance for 2022.

Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q2

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Christine Lindenboom – Senior Vice President-Investor Relations and Corporate Communications Yvonne Greenstreet – Chief Executive Officer Tolga Tanguler – Chief Commercial Officer Akshay Vaishnaw – President Jeff Poulton – Chief Financial Officer Conference Call Participants Paul Matteis – Stifel David Lebowitz – Citi Salveen Richter – Goldman Sachs Ritu Baral – Cowen Tazeen Ahmad – Bank of America Joseph Stringer – Needham Maury Raycroft – Jefferies Luca Issi – RBC Capital Gary Nachman – BMO Anupam Rama – J.P. Morgan Gena Wang – Barclays Eliana Merle – UBS Myles Minter – William Blair Olivia Brayer – Cantor Operator Hello, thank you for standing by.

Alnylam Pharmaceuticals, Inc. (ALNY) CEO Yvonne Greenstreet on Q2 2022 Results - Earnings Call Transcript

Alnylam (ALNY) delivered earnings and revenue surprises of -41.36% and 13.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Misses Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2022 and reviewed recent business highlights. “We're pleased with our second quarter results which delivered strong growth in both patient demand and product revenues. A notable achievement in the quarter was the recent approval of AMVUTTRA, which becomes our fifth RNAi therapeutic approved

Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company and collaborators have identified mutations in the INHBE gene associated with protection against abdominal obesity and metabolic syndrome – a condition impacting more than 20 percent of adults worldwide. The discovery leveraged sequencing data from more than 360,000 individuals in UK Biobank, and was published in the 13th issue of Nature Commun

Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of vutrisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy. If approved by the European Commission (

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy

Results from the APOLLO-B study are due any day now and will significantly impact sentiment around ALNY shares, as well as the revenue potential of Onpattro. A clearly successful outcome could quadruple revenue, but it's possible that the trial could meet its primary outcome and fail to show sufficient benefits in secondary outcomes (or vice versa).

Alnylam Pharmaceuticals Heading Toward A Key Trial Read-Out

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2022 on Thursday, July 28, 2022, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2022 results as well as expectations for the future via conference call on Thursday, July 28, 2022 at 8:30 am ET. To access the call, ple

Alnylam to Webcast Conference Call Discussing Second Quarter 2022 Financial Results

Baxter

Biogen

Boston Scientific

Cardinal Health

Gilead Sciences

Johnson & Johnson

Medtronic

Mirati Therapeutics

Natera

Roche Holding AG

Stryker

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

If you have the discipline to think long-term as an investor, this is the time to take advantage of the steep discounts on great biotechnology companies.

Seven reasons the beleaguered biotech sector is now a ‘buy'

The FDA approves Alnylam's (ALNY) Amvuttra (vutrisiran) to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

News for Alnylam Pharmaceuticals Stock (ALNY)